Literature DB >> 8080070

Inguinal lymph node metastases from adenocarcinoma of the rectum.

T W Mesko1, M A Rodriguez-Bigas, N J Petrelli.   

Abstract

This study is a retrospective review of 18 patients treated from 1964 to 1990 with inguinal lymph node metastases from rectal adenocarcinoma. Statistical analyses were performed to determine the effects of sex, disease-free interval, extent of inguinal lymph node metastases, and the presence of extranodal disease upon survival. The mean age of patients was 61 years (range 32 to 87). Lymph node metastases were unilateral in 12 patients and bilateral in 6. All 18 patients developed disease at loco-regional sites (pelvis/perineum) either synchronous or metachronous to their development of inguinal lymph node metastases. Survival from the time of diagnosis of inguinal lymph node metastases ranged from 2 to 54 months (median 13.5). There was no statistically significant difference in survival for unilateral versus bilateral inguinal metastases (P = 0.37). The median survival when inguinal lymph node metastases occurred > or = 12 months from diagnosis of the primary tumor was 16 months and 10.5 months when metastases occurred < 12 months after the diagnosis of the primary tumor (P = 0.033). The median survival for patients with isolated metachronous inguinal lymph node metastases was 20 months versus 12 months for patients who developed metachronous inguinal metastases concurrent with other areas of disease (P = 0.045). Although patients with disease-free intervals > or = 12 months and those with isolated inguinal metastases had statistically significant longer median survivals, the overall survival remains poor and all patients died with disease.

Entities:  

Mesh:

Year:  1994        PMID: 8080070     DOI: 10.1016/s0002-9610(05)80204-1

Source DB:  PubMed          Journal:  Am J Surg        ISSN: 0002-9610            Impact factor:   2.565


  8 in total

Review 1.  Unusual osseous metastases from rectal adenocarcinoma: a case report and review of the literature.

Authors:  T M Connelly; R P Piggott; R M Waldron; P O'Grady
Journal:  J Gastrointest Surg       Date:  2015-02-27       Impact factor: 3.452

2.  Adenocarcinoma of the proximal rectum and synchronous non-Hodgkin's lymphoma.

Authors:  Johnny Yap; Andrew Soh
Journal:  J Gastrointest Oncol       Date:  2013-03

3.  Sentinel lymph node in patients with rectal cancer invading the anal canal.

Authors:  D C Damin; G C Tolfo; M A Rosito; B L Spiro; L M Kliemann
Journal:  Tech Coloproctol       Date:  2010-04-28       Impact factor: 3.781

4.  Aberrant single metastasis to the elbow from primary rectal cancer: a rare presentation.

Authors:  Alessandro Bianchi; Marina Jimenez-Segovia; Jaume Bonnin-Pascual; Marga Gamundí-Cuesta; Myriam Fernandez-Isart; Monica Guillot-Morales; Diego Salinas-Gonzalez; Xavier Francesc Gonzalez-Argenté
Journal:  Pan Afr Med J       Date:  2020-08-31

5.  Is elective inguinal radiotherapy necessary for locally advanced rectal adenocarcinoma invading anal canal?

Authors:  Seung-Gu Yeo; Hyeon Woo Lim; Dae Yong Kim; Tae Hyun Kim; Sun Young Kim; Ji Yeon Baek; Hee Jin Chang; Ji Won Park; Jae Hwan Oh
Journal:  Radiat Oncol       Date:  2014-12-23       Impact factor: 3.481

6.  Anal adenocarcinoma requires prophylactic inguinal nodal treatment: Results from a single Chinese institution.

Authors:  Zhen Su; Zhan-Wen Guo; Yan-Ping Mao; Jie Tang; Xiao-Wen Lan; Fang-Yun Xie; Qun Li
Journal:  J Cancer       Date:  2017-04-09       Impact factor: 4.207

7.  Treatment of Inguinal Lymph Node Metastases in Patients with Rectal Adenocarcinoma.

Authors:  J A W Hagemans; J Rothbarth; G H W van Bogerijen; E van Meerten; J J M E Nuyttens; C Verhoef; J W A Burger
Journal:  Ann Surg Oncol       Date:  2019-02-06       Impact factor: 5.344

8.  Radiation boost for synchronous solitary inguinal lymph node metastasis during neoadjuvant chemoradiotherapy for locally advanced rectal cancer.

Authors:  Mo Chen; Shuai Liu; Meng Xu; Han-Chen Yi; Yanping Liu; Fang He
Journal:  Discov Oncol       Date:  2021-12-04
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.